ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1740

Orange Brown Chromonychia in Kawasaki Disease: A Clinical Sign That Merits Greater Attention

RAKESH KUMAR1, Ankur Kumar Jindal 2, Himanshi Chaudhary 1 and Surjit Singh 1, 1Allergy Immunology Unit, Department pf Pediatrics, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, Chandigarh, India, 2Allergy Immunology Unit, Department pf Pediatrics, Advanced Pediatrics Centre, Postgraduate Institute of Medical Education and Research, Chandigaarh, India

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Kawasaki disease and Nail

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: Pediatric Rheumatology – ePoster II: SLE, Juvenile Dermatomyositis, & Scleroderma

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose: Background: Peripheral signs in Kawasaki disease (KD) include erythematous swelling of hands and feet during acute phase, periungual desquamation and Beau’s lines on nails in convalescent phase. Orange–brown discoloration of nails has, however, not been frequently described in KD.

Methods: Although chromonychia was described by Pal et al way back in 2010, we had not been looking prospectively for this sign until very recently. We report 20 patients with KD and orange-brown chromonychia that were seen during the period May 2017 – February 2019.

Results: Median age at diagnosis in these patients was 1.4 years (range:3 months-4 years).  Seven patients were below 1 year. Eleven patients developed chromonychia in acute phase of KD, while in 9 this finding was identified in convalescent phase.  Associated atypical features that were seen in these patients included BCG reactivation in 2; macrophage activation syndrome in 2; uveitis in 1; peripheral gangrene in 1; bilateral parotidomegaly in 1; HIN1 pneumonia in 1.  Ten (50%) children required second line therapy – infliximab in 6; second dose of IVIg in 1; methylprednisolone in 3. Coronary artery abnormalities were seen in 5 patients and 2 had giant aneurysms – one in left main coronary artery; another in left main, left anterior descending and left circumflex coronary arteries. 

Conclusion: Transverse orange brown chromonychia is a useful clinical sign in KD and may be seen in both acute and convalescent phases of the disease. This sign can be easily missed if not looked for carefully. It appears to be more common in infants and young children and may be a marker of more severe disease. Presence of this sign may help pediatricians in arriving at a diagnosis of KD, especially in situations where the presentation is incomplete.

Figure 1:
A, B: Shows orange brown transverse lines -chromonychia- on all nails in patient 1
C: Chromonychia in patient 2
D: Chromonychia in patient 3
E, F: Orange brown chromonychia in convalescent phase patient 4
G: Peripheral gangrene in patient 5
F: BCG reactivation in patient 1


Disclosure: R. KUMAR, None; A. Jindal, None; H. Chaudhary, None; S. Singh, None.

To cite this abstract in AMA style:

KUMAR R, Jindal A, Chaudhary H, Singh S. Orange Brown Chromonychia in Kawasaki Disease: A Clinical Sign That Merits Greater Attention [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/orange-brown-chromonychia-in-kawasaki-disease-a-clinical-sign-that-merits-greater-attention/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/orange-brown-chromonychia-in-kawasaki-disease-a-clinical-sign-that-merits-greater-attention/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology